Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab and Fruquintinib in Advanced Non-liver-limited Metastatic Colorectal Cancer
NCT05954429Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Jul 2023
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Fragment-Derived Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of serplulimab, fruquintinib in colorectal cancer (CRC), sponsored by Fudan University. Started Jul 2023; status: recruiting.
02
Drugs
serplulimabfruquintinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05954429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05954429.